Acasti Pharma Reports Its Second Quarter Results

About Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) – (TSX.V.NTB)

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements"   within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such   forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause   the actual results of the Company to be materially different from historical results or from any future results expressed or   implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties,   readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates,"   "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject   generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the   Securities and Exchange Commission and the Canadian securities commissions.

CONTACT: Acasti Contact:
         Henri Harland
         President & CEO
         +1 450.687.2262
         [e-mail]
         www.acastipharma.com
         
         Xavier Harland
         Chief Financial Officer
         +1.450.687.2262
         [e-mail]
         www.acastipharma.com
         
         Howard Group Contact:
         Dave Burwell
         [phone]
         [e-mail]
         www.howardgroupinc.com

« First ‹ Previous 1 2